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Abstract Tissue transglutaminase (TG2) is a Ca2?-
dependent enzyme and probably the most ubiquitously
expressed member of the mammalian transglutaminase
family. TG2 plays a number of important roles in a variety
of biological processes. Via its transamidating function, it
is responsible for the cross-linking of proteins by forming
isopeptide bonds between glutamine and lysine residues.
Intracellularly, Ca2? activation of the enzyme is normally
tightly regulated by the binding of GTP. However, upreg-
ulated levels of TG2 are associated with many disease
states like celiac sprue, certain types of cancer, fibrosis,
cystic fibrosis, multiple sclerosis, Alzheimer’s, Hunting-
ton’s and Parkinson’s disease. Selective inhibitors for TG2
both cell penetrating and non-cell penetrating would
therefore serve as novel therapeutic tools for the treatment
of these disease states. Moreover, they would provide
useful tools to fully elucidate the cellular mechanisms TG2
is involved in and help comprehend how the enzyme is
regulated at the cellular level. The current paper is intended
to give an update on the recently discovered classes of TG2
inhibitors along with their structure–activity relationships.
The biological properties of these derivatives, in terms
of both activity and selectivity, will also be reported in
order to translate their potential for future therapeutic
developments.
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Abbreviations
TGase Transglutaminase
SAR Structure–activity relationship
HYD Hydrophobic
HBA Hydrogen bond acceptor
GTP Guanosine triphosphate
GDH Glutamate dehydrogenase
5-BP 5-Biotinamidopentylamine
tBoc tert-Butyloxycarbonyl
Cbz Benzyloxycarbonyl
Fmoc Fluorenylmethyloxycarbonyl
Ac Acetyl
Introduction
Transglutaminases are enzymes that perform post-transla-
tional modifications of proteins via an aminoacyltransfer-
ase reaction involving nucleophilic substitution at the
gamma amide of a peptide-bound glutamine, with elimi-
nation of ammonia. The nucleophile may be the e-amino
group of a peptide lysine, another primary amine or water.
In this way, e(c-glutamyl)lysine cross-links may be formed
between proteins, peptide glutamines may be derivatised
by primary amines, or peptide glutamines may be deami-
dated to glutamate. The protein cross-linking activity of
transglutaminases is one of the most understood, resulting
in the stabilisation of protein structures both against bio-
logical and mechanical degradation. Transglutaminases
have been described in microorganisms, plants, inverte-
brates, amphibians, fish, birds and mammals. In mammals,
transglutaminases are Ca2? activated and important for the
stabilisation of structures such as skin, hair and blood clots.
The most ubiquitous mammalian transglutaminase is tissue
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transglutaminase (TG2) and has been the subject of much
research due to its association with a variety of disease
states such as metastatic cancer, celiac disease, fibrosis and
neurodegenerative disorders. The role of TG2 in the
pathology of these diseases is still unclear, although tran-
samidating activity has been shown to be important. The
development of selective inhibitors that regulate TG2-
transamidating activity therefore have the potential to act
as novel therapeutic solutions. However, given the multi-
functional roles of the eight active members of the mam-
malian transglutaminase family (Chen and Mehta 1999;
Griffin et al. 2002), selectivity therefore concerns not only
being selective for inhibition of transglutaminases but also
being selective for inhibition of one or more of the trans-
glutaminase members. Moreover, selectivity for particular
transglutaminase members would help elucidate their spe-
cific biological roles.
To date, inhibitors of transamidation activity have been
generally classified in two distinct subclasses depending on
the inactivating mechanism of the enzyme: reversible
(competitive or non-competitive) and irreversible inhibi-
tion. The competitive inhibitors are typically derivatives
that include in their structure a medium to long saturated
aliphatic chain bearing a terminal primary amine. This type
of substrates were summarized previously (Lorand and
Conrad 1984) and include among others putrescine and
cadaverine-derived inhibitors, like 5-biotinamidopen-
tylamine (5-BP), monodansyl cadaverine, fluorescein
cadaverine (Fig. 1a–d). These type of compounds block
cross-linking by acting as competitive primary amine
substrates and become incorporated into thec-glutamyl
residue(s) of the peptide or protein substrate. Although
useful for in vitro studies, in vivo they have limited
application since the aminated protein could feasibly elicit
an autoimmune response. Moreover, they have the poten-
tial to act as competitive substrates for all the transgluta-
minase enzymes.
Many of the non-competitive reversible inhibitors
reported up-to-date allosterically inactivate the enzyme by
competing for the TG2 cofactor (GTP, GDP, etc.) binding
site. Thieno[2,3-d]pyrimidin-4-one acylhydrizides identi-
fied by Case and co-workers (Duval et al. 2005; Case and
Stein 2007) belong to this class of inhibitors (Fig. 1e).
However, when designing such compounds, it must be
taken into consideration that other members of the TG
family, e.g. TG3 and TG5 also bind guanine nucleotides
(Ahvazi et al. 2004; Candi et al. 2004).
Tissue transglutaminase irreversible inhibitors are prob-
ably the most widely studied type of TG2 inhibitors in the last
15 years. The majority target the active site CYS residue of
the mammalian TGs, and incorporate in their structure an
essential electrophilic warhead able to covalently react with
the highly nucleophilic sulphur atom from the catalytic site
CYS residue, therefore totally inactivating the enzyme.
Importantly, using the information gathered from the active
sites of crystal structures of TG3, Factor XIII and TG2 and
from information gathered from the preferred peptide amino
acid sequences acting as TGase substrates (Hitomi et al.
2009; Sugimura et al. 2011) they allow greater specificity to
be achieved against the target TG.
The classical approach to design irreversible inhibitors
was a ‘‘simplification’’ approach, which means designing
derivatives structurally related to their preferred natural
c-glutamyl-containing substrates, but with a simplified
chemical structure, more easy to modulate for the desired
pharmacological profile. Several series of peptidic
Fig. 1 Chemical structures of
some reversible TG2 inhibitors
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inhibitors emerged following this concept, the chemical
structure of the warhead being generally used to differen-
tiate among them (Fig. 2): 3-halo-4,5-dihydroisoxazoles
(Choi et al. 2005; Watts et al. 2006; Castelhano et al.
1988), epoxides (de Macedo et al. 2002; Marrano et al.
2001b), a,b-unsaturated amides (de Macedo et al. 2002;
Marrano et al. 2001b; Pardin et al. 2006), chloroacetamides
(Pardin et al. 2006), thiadiazoles (Marrano et al. 2001a),
maleimides (Halim et al. 2007; Pardin et al. 2006), sulfo-
nium methyl ketones (Pliura et al. 1992).
One of the most promising inhibitors described to date
belongs to the dihydroisoxazole family (KCC009, Fig. 2).
With a good pharmacokinetic profile and a good bio-
availability in mice, this compound was tested in a human
colon cancer cell line where it was shown to increase
chemo-sensitivity of the tumour (Choi et al. 2005) in the
range 1–100 lM. However, Verhaar et al. (2011) showed
that KCC009 was unable to affect TG2 activity up to a
concentration of 100 lM in their SH-SY5Y cell lines.
Contrarily, the 6-diazo-5-oxo-noerleucine (DON) deriva-
tive Z006 which penetrates into cells (Fig. 2) induced a
near complete inhibition of cellular TG2 at a concentration
of 10 lM (20-fold higher than in in vitro assays). More-
over, KCC009 does not affect the TG2-regulated formation
of Mallory Bodies inside hepatocytes (Strnad et al. 2006)
suggesting it may have limited intracellular activity.
Recently discovered classes of tranglutaminase 2
inhibitors
The main intention of this article is to review the recently
reported TG2 inhibitors along with their structure–activity
relationships (SAR) and their known specificity and
applications to date. For a comprehensive view on this
topic, the reader is also suggested to consult the previously
published reviews (Siegel and Khosla 2007; Wodzinska
2005).
Cinnamoyl derivatives as TG2 inhibitors
Starting from a comparative study between Cbz-Gln-Gly
versus Boc-Gln-Gly-binding modes via molecular model-
ing (Chica et al. 2004) but also from the privileged inter-
action of the benzyloxycarbonyl (Cbz) moiety from several
TG2 peptidic inhibitors with the enzyme’s binding site, the
group of Keillor further investigated the importance of
rigidity of this carbamate moiety (Pardin et al. 2008a).
Their efforts led to the identification of trans-cinnamoyl
derivatives as competitive reversible TG2 inhibitors
(Fig. 3), with IC50 values for guinea pig liver TGase
ranging from 18–[200 lM. The most potent inhibitors
were divided in two subclasses, depending on the nature of
the heteroaromatic substituent (HET) moiety: benzotriaz-
olyl or pyridinyl.
Initial SAR on the aromatic cinnamoyl scaffold showed
that substituents in the para position (preferably with a
sp2 hybridized oxygen, e.g. –NO2, BocHN–, FmocNH–,
AcNH–, –COOMe) positively influenced the affinity, while
other substituents (Me–, MeO–, Cl–) had an unfavourable
effect on binding. The observed IC50 values were as low as
18 lM in the case of p-BocHN substituent and a 3-pyridyl
as the HET moiety. The biological evaluation of their
flexible analogues (the alkene is reduced or replaced by
methylene-ether) showed a loss of activity. Moreover, the
introduction of a supplementary conjugated alkene was
Fig. 2 Examples of previously
reported peptidic irreversible
inhibitors
Recent advances in the development of TG2 inhibitors
123
detrimental to the TG2 affinity, compared to their shorter
analogues. Screening of several amines (aliphatic or aro-
matic) as the HET moiety had a negative impact on the
affinity, as well as Bz and tBuO ethers. The overall con-
ducted modulations showed that an aromatic moiety pos-
sessing hydrogen bond acceptors (HBA) is mandatory for a
good affinity in this series of compounds (Fig. 3). This
group of inhibitors seem to have a good selectivity profile
since no inhibition of FXIII or caspase-3 was detected up to
200 lM as showed by direct continuous colorimetric
assays (Leblanc et al. 2001).
Further development of this cinnamoyl series was
reported subsequently by the same group (Pardin et al.
2008b). Starting from the hypothesis that an aromatic
heterocycle containing HBA atoms was essential for a
good affinity (see above), various substituted triazoles were
synthesized and evaluated (Fig. 4).
The conducted modulations showed that an alkyl sub-
stituent on the triazole ring generally induced a onefold
increase of affinity. For example, compared to the parent
non-substituted triazole (IC50 = 45 ± 0.5 lM), introduc-
ing a benzyl substituent resulted in an IC50 decrease to
4.3 ± 0.3 lM. The interaction between the triazole sub-
stituent and the binding site is most probably hydrophobic,
since a cyclohexylmethyl substituent retains the affinity
(although slightly lower) compared to its aromatic ana-
logue (IC50 = 11.0 ± 1.5 lM vs. IC50 = 4.3 ± 0.3 lM).
The newly discovered inhibitor (Fig. 4) did not protect or
potentiate cell death induced by oxygen–glucose depriva-
tion when used on cells expressing wild type TG2. Up to its
toxicity limit (20 lM) it did inhibit ionomycin-induced
increases of transamidation activity for cells expressing the
wt TG2 and in cells transfected with the TG2-R580A
mutant (Colak et al. 2011).
Although the reversible cinnamoyl-based inhibitors
were in silico modelled to accommodate the acyl donor
substrate-binding site, further empirical proof was neces-
sary to sustain this hypothesis. A new derivative (Fig. 5)
incorporating a diazirine warhead was designed and
enabled photolabelling of TG2 residues in its proximity, in
the active-binding pocket (Pardin et al. 2009). Due to the
ability of alkyl diazirines to generate diazo and carbene
derivatives by photoactivation (Brunner 1993; Ziebell et al.
2004), this photolabile inhibitor was proved by mass
spectrometry to covalently react with the Cys230 residue.
Native polyacrylamide gel electrophoresis showed that the
enzyme-bound inhibitor adopts an open-form conformation
[analogous to the reported crystal structure resolved in
2007 (Pinkas et al. 2007)], despite contradictory molecular
modelling studies by the same authors, which suggested a
more solvent exposed Cys230 residue in the closed
conformation.
Inhibitors identified by the screening of libraries
Several potent hits for TGase were identified during high-
throughput screening assays (Lai et al. 2008) of two
libraries of pharmacologically active compounds: LOPAC
(1,280 cpds) and Preswick (880 cpds). The most interest-
ing derivatives validated via a first soluble-phase
Fig. 3 General structure of
cinnamoyl derivatives and their
SAR tendencies (Pardin et al.
2008a)
Fig. 4 General structure of
triazole transglutaminase
inhibitors and their SAR trends
(Pardin et al. 2008b)
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fluorescent dansylated lysine (KxD) incorporation assay
and a subsequent colorimetric biotinylated pentylamine
(BP) incorporation assay (which eliminate fluorescence
interference) were subjected to a Triton X-100 test, known
to eliminate false-positives induced by non-specific small-
molecule aggregates (McGovern et al. 2003). Figure 6
summarizes the most interesting hits found following this
approach.
All the compounds inhibited TG2 irreversibly in the
presence of Ca2?. However, when reducing agent DTT was
included in the transglutaminase reaction their activity was
significantly reduced, which the authors suggested was due
to the inhibitors promoting the formation of disulfide bonds
that inactivated the enzyme. Surprisingly, in the absence of
Ca2? several ligands were found to reversibly bind to the
enzyme but Tyrphostin-47 was the only inhibitor, which
competed with the GTP for its binding to TG2. Concerning
the selectivity profile, beside their original protein targets
listed in the screening database, the compounds were tested
against blood coagulation factor FXIII, by using the same
biotin pentylamine incorporation assay. They were found
to be equipotent for FXII as for TG2, except for the vitamin
K3, which had a sixfold decrease of affinity for FXIII.
A more complete biological profile for these hits, but
also for other several classes of transglutaminase inhibitors,
was reported by Macdonald and co-workers (Schaertl et al.
2010). During their efforts for developing a profiling
platform for characterizing TG2 inhibitors, the authors
investigated the TGase activity over a panel of transglu-
taminase isoforms (TG1, TG2, TG3, TG6 and FXIII), but
also conducted a number cell activity studies and toxicity
assays. However, it should be mentioned that, in the case of
cellular assays, no data indicating the membrane perme-
ability were reported. The biological results for the hits
previously discovered by screening (Lai et al. 2008) are
presented in Table 1.
Beside the biological characterization of previously
reported inhibitors, the authors also revealed the SAR for
new quinazolinone derivatives. Developed from the acy-
lhydrazides published by Cuny and co-workers (Duval
et al. 2005), their efforts led to the discovery of a highly
potent (20 nM) and selective inhibitor for TG1, TG3 and
FXIII. However, no specific structures and additional cel-
lular data were disclosed. The overall SAR trends in this
series are presented below (Fig. 7).
b-Aminoethyl ketones as TG2 inhibitors
Even if the IC50 of the previously reported hit ZM 39923
[IC50 = 0.01 ± 0.01 lM (Lai et al. 2008); Fig. 6] was
found to be only 4 lM in their activity assays, this deriv-
ative was the starting point of an extensive SAR study
published by Mikoshiba and co-workers (Ozaki et al.
2010). The authors stated that the original b-aminoethyl
ketone framework proved essential for the TGase binding,
contrary to their a- or l-aminoalkyl ketone analogues.
Various aromatic ketones in both carbocyclic and hetero-
cyclic series were investigated: heteroaromatic ketones
appeared to be more favoured compared to the aromatic
substituents, thiophene and furan showing the best results.
The most potent ligand from this series as well as the SAR
Fig. 5 Structure of the cinnamoyl photolabile inhibitor (Pardin et al.
2009)
Fig. 6 Hits discovered via a
HTS approach (Lai et al. 2008)
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trends from the investigated compounds are presented
below (Fig. 8).
In relation to the well-known affinity of disulfide com-
pounds for transglutaminases (Connellan and Folk 1969;
Chung and Folk 1970), of which recent examples include
cystamines (Okauchi et al. 2009), the group of Mikoshiba
has developed a series of disulfide dimers starting from the
same b-aminoethyl ketone building block (Ozaki et al.
2011). This new series of derivatives, when tested for their
effects on TGase activity (Ozaki et al. 2010), showed
affinities in the 0.12–19 lM range. Again, the thienyl
ketone substituent conserved the best interaction with the
Table 1 IC50 (lM) values
obtained for the screening hits
(see Fig. 6 for molecular
structures), modified from
(Schaertl et al. 2010)
Compound hTG2 mTG2 Cellular TG2 hTG1 hTG3 FXIIIa Caspase-3 Tox
GW 5074 4.6 10.6 1 5.7 2.7 3.9 70 25
ZM 39923 2.8 1 [50 2.9 [80 1.7 47 50
Tyrphostin 47 45 59 [50 16 6.4 11.4 [50 0
NSC 95397 1.3 2.1 [50 0.93 0.5 0.41 [50 30
b-Lapachone 0.75 1.1 [50 0.6 0.38 0.37 0.19 3
Menadione 2.6 6.6 [50 2.9 1.8 2.1 6 20
Fig. 7 SAR trends of
acylhydrazides (Duval et al.
2005; Schaertl et al. 2010)
Fig. 8 SAR trends and the most
potent derivative in
b-aminoethyl ketone series
(Ozaki et al. 2010)
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binding site of TG among all the tested aromatic substit-
uents (Fig. 9).
Oxindole-based TG2 inhibitors
The screening of the Navigator’s iResearch library for TG2
inhibitors by Griffin and co-workers, led to the identifica-
tion of various 2-oxindoles derivatives with TGase inhib-
itory activity (Klock et al. 2011). Besides some dimers with
lM affinity for TG2, the screening also identified a more
interesting compound, prone to further pharmacomodula-
tions: 2-acylidenoxindole (Fig. 10). It is worth mentioning
that the same scaffold was discovered earlier (Lai et al.
2008) during their screening assays (compound GW 5074,
Fig. 4). Modulation of substituents R1, R2 and R3 (Fig. 10)
showed that the oxindole’s aromatic moiety is the most
sensitive region of the molecule for the interaction with the
TG2-binding site, a –Br or –Cl substituent on C4 enhancing
the activity for at least sixfold compared to their unsub-
stituted analogues.
As underlined in Fig. 10, the compounds were submit-
ted to two different binding assays, a GDH-coupled assay
and a more sensitive coumarin-based fluorescence assay,
which allows the use of the TG2 enzyme at concentrations
below 100 nM. Interestingly, this fluorometric assay
showed that several compounds from this series acted
either as partial inhibitors or non-competitive, allosteric
inhibitors.
Recently discovered peptidic TG2 inhibitors
In an extension to their previous studies on the peptidic
dihydroisoxazoles (Watts et al. 2006) as TG2 inhibitors,
Dafik and Khosla (2011) recently reported new derivatives
with interesting TGase inhibitory activity. Developed for
labelling and visualizing the catalytically active form of
TG2, these compounds incorporate reactive azido or
alkynyl functional groups designed for trapping fluoro-
phores or different tags by using alkyne-azide ‘‘click’’
chemistry, as illustrated previously in the literature (Sletten
and Bertozzi 2009). The conducted modulations also
included the aminoacid moiety in Trp, Tyr or Pro series,
the overall SAR trends, observed using kinetic assays on
Fig. 9 SAR tendencies for the dithio-b-aminoethylketones (Ozaki
et al. 2011)
Fig. 10 Initial hit from
screening, SAR trends and the
most potent compound in
oxindole series (Klock et al.
2011)
Fig. 11 SAR trends and one
example of inhibitor from the
recently reported peptidic
dihydroisoxazoles (Dafik and
Khosla 2011)
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hTG2, are presented bellow (Fig. 11). Some of the syn-
thesized compounds were also tested in a tissue culture
wounding model, using the concept validated earlier
(Siegel et al. 2008), the most potent inhibitors completely
blocking TG2 activity around the ‘‘wound’’ at concentra-
tions as low as 3.1–6.25 lM.
In their search for aqueous soluble TGase inhibitors that
could target preferentially the extracellular pool of TG2,
since many of the pathologies that the enzyme is involved
in such as fibrosis, celiac disease, multiple sclerosis and
cancer are either wholly or partially limited to the extra-
cellular space, Griffin et al. (2008) developed a series of
sulfonium peptidylmethylketones related to those pub-
lished by Pliura et al. (1992). The carboxylic acid and the
dimethylsulfonium moieties are key distinguishing features
that increase the compound’s solubility in water, due to the
presence of charges at physiological pH. Beside the vari-
ation of the central aminoacid core, the authors also
investigated the modification of the carbamate moiety
(Fig. 12). Several other warheads based on the imidazoli-
um scaffold could also be tolerated or even enhance the
TGase activity (Griffin et al. 2004). Members of this series
of compounds have been used successfully in cell studies
(Baumgartner et al. 2004; Jones et al. 2006; Telci et al.
2009) and in preclinical studies of diabetic nephropathy
and kidney scarring where they induced no animal toxicity
up to 120 days and successfully reduce kidney fibrosis and
scarring by up to 85% with a significant increase in kidney
function (Johnson et al. 2007, 2008; Huang et al. 2009)
Concluding remarks
The increasing discovery of tissue transglutaminase
involvement in many physiological processes and disease
states make it an attractive therapeutic target. Publications
in this area are constantly increasing, with the last 4 years
being extremely rich in new classes of discovered inhibi-
tors. The usefulness of the screening approaches used for
the identification of new active compounds has been con-
firmed by a number of groups. The reported crystal struc-
tures for three of the TG family have further aided inhibitor
design and in the case of TG2 revealed the complex con-
formational dynamics of this multifunctional enzyme. This
has led to a more rational drug design phase which no
doubt will expand in the immediate future leading to fur-
ther improvements in the potency and selectivity of pos-
sible drug candidates. However, the discovery of a first
drug that alleviates one of the disease states that TG2 is
involved in by modulation of enzyme function remains a
challenging task for the research community.
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